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Abstract
Background: The early and intermediate outcome of patients requiring intraaortic balloon pump (IABP) was
studied in a cohort of 2697 adult cardiac surgical patients.
Methods: 136 patients requiring IABP (5.04%) support analysed over a 4 year period. Prospective data collection,
obtained.
Results: The overall operative mortality was 35.3%. The “operation specific” mortality was higher on the Valve
population.
The mortality (%) as per time of balloon insertion was: Preoperative 18.2, Intraopeartive 33.3, postoperative 58.3
(p < 0.05).
The incremental risk factors for death were: Female gender (Odds Ratio (OR) = 3.87 with Confidence Intervals
(CI) = 1.3-11.6), Smoking (OR = 4.88, CI = 1.23- 19.37), Preoperative Creatinine>120 (OR = 3.3, CI = 1.14-9.7), Cross
Clamp time>80 min (OR = 4.16, CI = 1.73-9.98) and IABP insertion postoperatively (OR = 19.19, CI = 3.16-116.47).
The incremental risk factors for the development of complications were: Poor EF (OR = 3.16, CI = 0.87-11.52),
Euroscore >7 (OR = 2.99, CI = 1.14-7.88), history of PVD (OR = 4.99, CI = 1.32-18.86).
The 5 years survival was 79.2% for the CABG population and 71.5% for the valve group. (Hazard ratio = 1.78,
CI = 0.92-3.46).
Conclusions: IABP represents a safe option of supporting the failing heart. The need for IABP especially in a high
risk Valve population is associated with early unfavourable outcome, however the positive mid term results further
justify its use.
Background
Intra-aortic balloon pump (IABP) is the most usable
tool of temporary mechanical circulatory support for
cardiac surgical patients suffered from low cardiac out-
put in the early postoperative phase. Only in United
States, more than 70.000 patients are supported
annually by IABP [1,2]. Its beneficial action is attribu-
ted to a concomitant reduction in afterload of left ven-
tricle with a substantial increase on coronary perfusion
pressure due to an increased of aortic diastolic
pressure [3,4].
The main indication of IABP use in cardiac surgical
patients is peri-operatively in the treatment of a low
cardiac output state refractory to the usual inotropic
support. Furthermore, it has been used prior to surgery
in patients having sustained mechanical complications
following myocardial infarction, as well as in patients
with refractory angina [5-7].
The hospital and also the 30-day mortality for
the patients necessitating IABP is high because of the
cardiac problems that led to the need for this pump,
ranged from 26% to 50% [2,6,8].
Aim of this study was to analyse our clinical experi-
ence with IABP in a high risk cohort of operated
patients. It includes a risk analysis by means of looking
into variables predicting mortality and early adverse
outcome. In addition, the 5-year survival was reported.
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Within a 4 year period between January 2000 and
December 2004, 2697 consecutive adult patients under-
went cardiac surgery; 136 patients (5.04%) required sup-
port with IABP. The mean age was 66.3 +/- 9.9 years
(range from 39 to 82 years).
There were 99 (72.8%) males and 37 (27.2%) female
patients. First operation was carried out in 119 patients
(87.5%) and re-operations in 17 patients (12.5%). Brake
down of the referrals showed elective 24.3%, urgent
50.7%, emergency 19.9% and salvaged operations in 5.1%
of the cases. 16.9% of the patients were diabetics.
Data pertaining to the patients past medical history
were studied and also variables (see Table 1) including
age, gender, diabetes mellitus, hypertension, high choles-
terol, smoking, history of peripheral vascular disease,
BMI, preoperative NYHA classification, ejection fraction,
history of previous myocardial infarction, serum creati-
nine, Euroscore, previous cardiac operations, indication
and timing for IABP insertion, operative priority, the
nature of the operation, cardiopulmonary bypass time
and status following the procedure. The myocardial pro-
tection of choice was Blood cardioplegia solution deliv-
ered every 20 minutes in an antegrade fashion.
The indications for initiating treatment with IABP in
this cohort of patients was the following: a) IABP sup-
port for persistent preoperative ischemia despite maxi-
mum medical treatment b) patients not able to be
discontinued from CPB although forced inotropic sup-
port, c) patients in low-cardiac output status just after a
“difficult” discontinuation of CPB, supported by high-
doses of inotropes, d) patients with “difficult” disconti-
nuation from CPB and spontaneous appearance of
arrhythmia (premature ventricular beats or VT) not
amenable in anti-arrhythmic continuous infusion and e)
post cardiotomy low cardiac output syndrome. Prophy-
lactic initiation of IABP treatment was not advocated in
any of the cases. A Datascope system (Datascope Corp,
Paramus, NJ) was utilised. The IABP was introduced
percutaneously through the common femoral artery in
131 patients and through an open access of the femoral
artery in the remaining 5 patients.
Correct placement of the device was routinely con-
firmed with Chest X Ray in ICU. Once mediastinal drai-
nage was minimum (< 50 ml/h), patients were
anticoagulated with Heparin infusion, keeping the
ACT >180-200 sec. Routine administration of a Cefalos-
porin 2
nd generation in combination with vancomycin,
through out the IABP support, was maintained.
Statistical analysis
Collection of the data is served using the Patients Ana-
lysis and Tracking System (PATS) software. Eighty vari-
ables were prospectively collected and carefully validated
before being analysed.
Categorical variables were tested using a qui square
test or Fisher exact test (two-tailed), and continuous
variables were tested using Students t test (two-tailed).
A p Value of less than 0.05 was regarded as statistical
significant. All calculatio n sw e r em a d eu s i n gS P S S1 1
edition. Operative mortality is reported as 30 day mor-
tality. Long term survival data were obtained by send-
ing questionnaires to the medical practitioners (98.5%
response). The median period of follow up was 64 ±
11 months. Survival analysis was performed according
to Kaplan-Meier method using life tables. Survival
rates were given as cumulative survival +/- standard
error.
Results
The CABG, Valve and CABG and Valve population
requiring IABP consist off 58.8%, 10.3% and 16.2% of
the total number of patients treated with an IABP.
The mean Euroscore of the patients requiring IABP
was 8.43 ± 4.5 (range 4 to 16).
Preoperative intraaortic balloon pump support
Twenty two patients underwent IABP support preopera-
tively (16.2%). There was one elective case due to
intractable angina (4.5%) and 8(36.3%) urgent cases
(operated on at the same hospital admission) due to
angina refractory to medical treatment. Eleven cases
Table 1 The pre- and intra-operative data of the patients
supported with an IABP.
General characteristics
Number of patients 136
Male/female 99/37
Age (y/s) 66.3 ± 9.9
Height (cm) 171 ± 8
Weight (kg) 79 ± 10
BSA 1.77 ± 9.3
Hypertension 42 pts
Diabetes mellitus 24 pts
Euroscore 8.43 ± 4.5
Significant Left main CAD 17 pts
Ischemic mitral regurgitation 2+/4+ 12 pts
Ejection fraction < 30% 49 pts
Operation’s-time (min) 365 ± 52
Cardiopulmonary bypass-time (min):
CABG 102.1 ± 34.72
AVR & CABG 161.5 ± 38.2
Complex Cases 205 ± 38
Myocardial ischemia-time (min) 89 ± 23
Post op Cardiac Index (L/min/m
2) 2.4 ± 1.7
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operation within 24 hours from the cardiology referral
and 2 cases (9.2%) were in severe cardiogenic shock and
were deemed salvaged.
Four patients died (mortality 18.18%) two from the
emergency group & also the two patients operated on
under salvaging conditions.
Intra-operatively intraaortic balloon pump support
Intra-operatively, ninety patients (66.2%) needed
intraaortic balloon inserted following failure to be
weaned off cardiopulmonary bypass. The overall mortal-
ity for this subgroup was 33.33% (30 patients).
Post-operatively intraaortic balloon pump support
Post operatively, twenty-four patients (17.6%) needed
intraaortic balloon inserted due to low Cardiac output
syndrome. The mortality of this subgroup was high,
58.33% (14 patients).
Breaking down the procedures
The incidence of patients needed IABP support per year
was between 4.2 and 5% with a mean incidence of 4.3 ±
0.6.
The Coronary artery bypass graft (CABG) population
Out of 1919 CABG patients operated on (mean Euro-
score 3.71 ± 1.25) over the same period (5% of those
patients had an Ejection Fraction less than 30% with an
overall mortality of 12.5%) eighty patients required IABP
(4.17%).
Out of the entire subgroup requiring IABP, 3 patients
underwent off pump CABG and 77 patients on pump.
The mean CPB time was 102.1 ± 34.72 minutes.
The overall mortality of the subgroup requiring IABP
was 16 patients (21.2%). There were 63 males (78.8%)
and 17 females (21.2%). The mortality for the males was
14.28% and for the females 41.17% (p < 0.05). Nine
patients requiring IABP support underwent a redo-
CABG (11.25%) with a mortality of 11.1%.
CABG and Valve population
Out of 211 CABG & Valve patients operated on over
the same period, twenty two patients (10.42%) required
support with IABP. 152 patients underwent CABG and
AVR out of which 9 patients (5.92%) required IABP.
There were 53 GABG and MVR patients out of which
13 patients (24.5%) required IABP.
This subgroup consists of 13 males (59.1%) and 9 females
(40.9%). The mean CPB time was 161.5 ± 38.2 min.
The overall mortality was 11 patients (50%). The mor-
tality for the males was 53.84% and for the females 44.
44%.
CABG and other
This group of patients consists of a high risk population
of eleven patients. Six out of them underwent CABG &
Ischemic Ventricular Septal Defect (VSD) repair with
mortality of 50%.
Valve population
Out of the total population of 281 AVR valves operated
on during the study period, 7 patients (2.5%) required
IABP. Out of the total population of 85 MVR valves, 4
patients (4.7%) required IABP. Out of the total popula-
tion of 25 Double valves 3 patients (12%) required
IABP. The overall mortality of the group was 9 patients
(see Table 2). Although the mortality was high in this
group of patients one has to state that the numbers
reported are very small to derive conclusions.
Redo-operations
Out of 136 patients requiring IABP support, 17 cases
were redo-operations (12.5%). Nine patients have had
redo CABG, three had AVR/MVR and CABG, one had
CABG and Aortic root replacement, one had CABG and
aneurysm on a previous saphenous vein, and two
patients underwent second time MVR operations. The
overall mortality for the group was 27.1%.
Others
From all 11 patients with post infarction VSDs over the
4 year period, 6 patients died (Mortality 54.5%). In all
these patients a preoperative IABP support had been
applied.
Eight patients underwent pericardiectomy (without
CPB) and 2 of them developed early postoperatively low
cardiac output syndrome; they were supported with an
IABP and died (mortality of 25%).
Table 2 Procedures requiring IABP & mortality
Procedures Number Percent Mortality
CABG only 80 58.8 16 (21.2%)
CABG + Valve 22 16.2 11 (50%)
CABG + Other 11 8.1 6 (54.5%)
CABG & VSD (6) 3
CABG & Lung Biopsy (1) 1
CABG & Aortotomy & Exploration LV (1) 1
CABG & LV Aneurysectomy (1) 0
CABG & Root Replacement (1) 0
CABG & SVG Aneurysm (1) 1
Valve Only 14 10.3 9 (64.3%)
Valve + Other 2 1.5 0
Other 7 5.1 6 (85.3%)
136 entries 48 patients
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The overall 30 day mortality was 35.3%. The mortality
w a sm a i n l yd u et oas e v e r el o wc a r d i a co u t p u ti n1 7
patients (12.5%), intractable sepsis 13 patients (9.6%)
(MRSA 6, VRE 1, other 6), cardiac arrest 13 patients
(9.6%), stroke 2 patients(1.5%), Ischeamic bowel 1(0.7%),
Pancreatitis 1(0.7%), GI bleed 1 (0.7%).
A regression analysis (Table 3) taking into considera-
tion all the variables mentioned at Materials and Meth-
ods, revealed that a female smoker with renal
impairment who undergoes a complex lengthy proce-
dure requiring IABP, has the higher mortality.
The incremental risk factors for development of com-
plications were: Poor EF (OR = 3.16, CI = 0.87-11.52),
Euroscore >7 (OR = 2.99, CI = 1.14-7.88), PVD (OR =
4.99, CI = 1.32-18.86).
The subgroup of patients required IABP support com-
pare to the rest of the cardiac surgical population had a
higher incidence of reoperation for bleeding (11.8% Vs
4.5%), prolong ventilation (42.6% Vs 7%), re-intubation
rate (18.4% Vs 4.9%), tracheostomy rate (9.6% Vs 1.2%)
and new dialysis required (23.5% Vs 4.9%).
Follow up/Survival
Actuarial survival curve for the entire group is presented
in Figure 1. Cumulative survival for the entire group was
85.2% at 4 years. There was a difference in survival
between GABG and Valve subgroups as per Figure 2.
According to this the 5 years survival was 79.2% for the
CABG versus 71.5% for the valve subgroup. (Hazard
ratio = 1.78, CI = 0.92-3.46).
Discussion
The need for increased use of IABP during cardiac sur-
gery in the recent years has been reported by many
groups [5,9]. This is mainly due to the fact that the
patient population has changed and now includes older
patients with multi-vessel disease and more impaired
ventricles. On the other hand, there is a lower threshold
for IABP use due to improve technology and lower rate
of complications [5].
In our series IABP used in 5% of the cases, however
its use was increased to 24.5% in patients requiring
MVR and CABG procedure. This probably reflects the
severity of LV dysfunction and the high incidence of
low cardiac output syndrome in this group of patients.
As per other groups [10] the majority of the devices
were inserted pre and intra operatively (82.4%). The pre-
operative indications were mainly unstable coronary
syndrome with multivessel disease refractory to maxi-
mum medical therapy or symptomatic coronary disease
with hemodynamic instability. IABP was not used for
“prophylactic reasons"; it is unclear in the literature as
to which patients would benefit from IABP support
prior to surgery [11,12]. Some institutions however, they
use the device too early and too often and they claim
lower overall mortality [13].
The CPB time was prolonged (205 ± 38 min) for the
complex cases. That was most probably due to: bleeding,
ap r o l o n g“resting on CPB” after aortic cross-clamp
removal because of difficulties in weaning from CPB
and also a rather high threshold for intraoperative IABP
insertion.
Ninety patients had intraaortic balloon inserted intrao-
peratively with a mortality of 33.3%. We attempt to split
the intraoperative IABP insertion patient group into
subgroups depending on time of IABP insertion and
compare the outcome; however it became apparent that
this was not feasible because the number of patients in
those subgroups were too small to demonstrate any
differences.
Through out the literature the mortality rates range
widely from 7% to 86% [14,15]. This is probably due to
the heterogeneous groups of patients considered. With
the wide range of indications some series have included
low risk patients, whereby the device was inserted pro-
phylactically, with subsequent favourable outcome. The
overall mortality in our series was around 36%. This
obviously reflects a population of high risk patients. The
mean age was high and also the percentage of patients
operated on for a reason other than CABG was 41.2%.
Comparing the overall mortality of the CABG patients
needed the IABP device versus the entire CABG popula-
tion with a poor EF we found that the first group has
higher mortality 20% Vs 12.5%. Furthermore, higher
Table 3 Multivariate logistic regression analysis of the
risk factors influencing mortality
Status O.R. 95% C.I.
Risk factor alive dead p value
Gender male 65 32 1.00
female 20 15 3.87 1.30 11.6 0.015
Smoking No 33 9 1.00
Yes 13 10 4.88 1.23 19.37 0.024
Ex 39 28 3.62 1.20 10.98 0.023
Pre Op Creatinine <=120 70 32 1.00
>120 15 15 3.33 1.14 9.70 0.027
Cross Clamp Time <=80 66 22 1.00
>80 19 25 4.16 1.73 9.98 0.001
IABP pre op 16 4 1.00
intra op 59 29 4.27 0.95 19.15 0.058
post op 10 14 19.19 3.16 116.47 0.001
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Figure 2 Survival curves for the CABG group Vs Others.
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group that required treatment with IABP. The percen-
tage of valve surgery patients requiring IABP is smaller
(2.5%) compare to the CABG population. Therefore in
our series out of a total number of 391 patients requir-
ing single or double valve replacement (aortic ± mitral)
14 patients were supported with IABP. Nine patients
died (64.3%). This is a group of patients with severe car-
diogenic shock whereby the IABP was used post opera-
tively with no real influence on the adverse outcome.
Timing of insertion and operative mortality has been
reported by few groups [10,16] with outcome similar to
our study. Like others [16] the lowest mortality was
observed in elective male CABG patients to whom the
IABP device had been inserted preoperatively. It is pos-
sible that better survival associated with preoperatively
IABP insertion is predictable due to the fact that this
subgroup is mainly suffer from intractable unstable
angina in comparison to the subgroup requiring IABP
support following peri or postoperative cardiogenic
shock. Nevertheless, one would argue that optimal pre
anaesthetic induction support with IABP minimizes
perioperative ischemia and inotropic use and therefore
reduces the incidence of postoperative cardiogenic
shock. In summary, although this report failed to pro-
duce robust data, it showed a trend towards positive
outcome when the IABP was inserted preoperatively.
Incremental risk factors for perioperative death have
been reported by various investigators [10,17,18]. In a
large retrospective study by Torchiana et al [17] inde-
pendent predictors of death were age, MVR, prolonged
CPB time, emergency operation, preoperative renal dys-
function, ventricular arrhythmias, right ventricular fail-
ure and emergency reinstitution of cardiopulmonary
bypass. In another elegant study by Arafa et al [18]
serum creatinine levels, EF, perioperative MI, timing of
IABP insertion and indication for operation were inde-
pendent predictors of early death. Although our study
includes smaller number of patients the incremental risk
factors for early death are similar with the aforemen-
tioned reports.
Surprisingly the overall mortality for redo CABG
patients requiring IABP treatment was at around 11%.
This is probably due to the fact that in the majority of
those cases the EF was only moderate impaired and the
IABP was inserted prophylactically preoperatively under
stable circumstances.
The complication rates are higher in older studies
[5,10,19,20] and lower in more recent publications
[21-23]. In our study, IABP support was found to be
associated with considerably higher morbidity, by means
of prolonged Intensive Care Unit stay, CVVH support
and tracheostomy rate. Those findings reflect the
importance of multidisciplinary approach for providing
care in this high risk subgroup.
In our report, cold pulse-less leg was detected in 1/4
of the cases. In 18 patients the ischemia resolved when
the IABP was removed and in 8 patients following
thrombectomy. Similar to other reports [21,24], poor EF
and history of peripheral vascular disease were the
incremental risk factors for development of vascular
complications. In addition, Euroscore above 7 reflected
the severity and comorbidity of the preoperative status
of such patients.
Finally the cumulative survival of 85,2% in 4 years is
rather higher compare with other groups[5,18,25].
Moreover there was a trend towards higher survival on
the CABG population. (The 5 years survival was 79.2%
for the CABG versus 71.5% for the valve group. (Hazard
ratio = 1.78, CI = 0.92-3.46).
Conclusions
This is a report of ongoing clinical practice. The sub-
groups (valves etc) of the patients supported with IABP
are small; therefore the derived results should be taken
with skepticism. The weaknesses of the study are due to
its observational character; furthermore there may also
be a selection bias for patients supported (ie.pre/post-
operatively) with an IABP, due to individual clinical
practices patterns. Lastly, variables that were not col-
lected from the database (PATS) were obviously missed
out from the multiple logistic regression analysis model.
In summary the peri-operative mortality of patients
needed IABP support remains high. The mortality is
increased exponentially when low cardiac output occurs
in ischemic female population who also required conco-
mitant valve surgery.
Nevertheless the use of IABP is justifiable. With
respect to timing of IABP insertion, the literature is
lacking on well defined guidelines. There is a trend to
suggest that earlier use of the device is associated with
better outcome possibly due to a better myocardial pro-
tection, but this remains to be tested with appropriate
trials.
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